Exagen Inc. Reports Third Quarter 2026 Financial Results
Globe Newswire•10/11/2026•07:30 ET
0
Key Highlights
- ➤Q3 revenue $18.4 million, up 7% year over year
- ➤2026 revenue guidance reiterated at $72 million to $75 million
- ➤Net loss narrowed 12% to $6.3 million in Q3
- ➤Adjusted EBITDA loss improved over 30% to $1.9 million
- ➤Myositis offering remains on track for early 2027 launch
Expert Statements
John Aballi, President and Chief Executive Officer of Exagen
“Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year.”
John Aballi, President and Chief Executive Officer of Exagen
“Beyond our financial performance, our strong showing at ACR Convergence demonstrates that our science continues to push the boundaries of traditional autoimmune care. We also remain on track to launch our myositis offering early in 2027, bringing greater clarity and confidence to clinicians and patients in an area of significant need.”
Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30%
CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a precision medicine company bringing clarity to autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and recent corporate updates.
Get started
Create a free account to read the full story.